Lilly’s Prasugrel Overcomes Cancer Hurdle, Receives Favorable Panel Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Cardio-Renal Advisory Committee says cancer risk possibly associated with the platelet inhibitor does not warrant strong warning in label or use restrictions.
You may also be interested in...
Effient Review Delayed More By Management Issues Than Clinical Disputes
Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate
Effient Review Delayed More By Management Issues Than Clinical Disputes
Review management issues, more than unresolved clinical debates, are what produced FDA's lengthy and overdue review of Lilly/Daiichi Sankyo's antiplatelet agent Effient (prasugrel), FDA review documents indicate
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
FDA cleared Lilly/Daiichi Sankyo's oral platelet inhibitor Effient (prasugrel) at both 5 mg and 10 mg doses on July 10, with a carefully constructed label that reflects the level of regulatory consideration - and negotiation - that went into the approval